Form 4: Celldex Therapeutics Executive VP & CSO, Tibor Keler, Reports Stock Option Grant

Tibor Keler, Executive VP & CSO of Celldex Therapeutics, reports the acquisition of 93,000 incentive stock options.

Summary

• Tibor Keler, Executive VP & CSO of Celldex Therapeutics, filed a Form 4 with the SEC.
• The filing reports the grant of 93,000 incentive stock options on June 13, 2024, at an exercise price of $36.43.
• The options vest 25% on June 13, 2025, and the remainder vest quarterly over the subsequent 12 quarters.
• The options expire on June 13, 2034.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to executive compensation, and does not contain information that would significantly impact sentiment.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Option grants are a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry, used to incentivize performance and align management's interests with those of shareholders.
• The size and vesting schedule of the grant are typical for executives at similar-sized biotech companies.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.

Key Dates